In addition, in a clinical cohort of 1005 tumors, we showed that CDK6 overexpression in p53 mutated tumours was associated with poor survival while CDK6 overexpression did not show association with patient survival in p53 wild type tumours. This evidence concerns the gene TP53 and neoplasm.